

Research Article

K₃EDTA Vacuum Tubes Validation for Routine Hematological Testing

**Gabriel Lima-Oliveira,^{1,2,3,4} Giuseppe Lippi,⁵
Gian Luca Salvagno,¹ Martina Montagnana,¹ Giovanni Poli,¹ Giovanni Pietro Solero,¹
Geraldo Picheth,² and Gian Cesare Guidi^{1,2}**

¹Laboratory of Clinical Biochemistry, Department of Life and Reproduction Sciences, University of Verona, 37129 Verona, Italy

²Post-Graduate Program of Pharmaceutical Sciences, Department of Medical Pathology Federal University of Parana, 80210-170 Curitiba, PR, Brazil

³MERCOSUL: Sector Committee of Clinical Analyses and In Vitro Diagnostics—CSM 20, 20270-902 Rio de Janeiro, RJ, Brazil

⁴Brazilian Society of Clinical Analyses on Sao Paulo State, 02965-140 Sao Paulo, SP, Brazil

⁵Laboratory of Clinical Chemistry and Hematology, Department of Pathology and Laboratory Medicine, Academic Hospital of Parma, 43126 Parma, Italy

Correspondence should be addressed to Gabriel Lima-Oliveira, dr.g.lima.oliveira@gmail.com

Received 16 April 2012; Accepted 10 June 2012

Academic Editors: D. Lavelle, W. Lösche, and C. Martinez

Copyright © 2012 Gabriel Lima-Oliveira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Objective. Some in vitro diagnostic devices (e.g., blood collection vacuum tubes and syringes for blood analyses) are not validated before the quality laboratory managers decide to start using or to change the brand. Frequently, the laboratory or hospital managers select the vacuum tubes for blood collection based on cost considerations or on relevance of a brand. The aim of this study was to validate two dry K₃EDTA vacuum tubes of different brands for routine hematological testing. *Methods.* Blood specimens from 100 volunteers in two different K₃EDTA vacuum tubes were collected by a single, expert phlebotomist. The routine hematological testing was done on Advia 2120i hematology system. The significance of the differences between samples was assessed by paired Student's *t*-test after checking for normality. The level of statistical significance was set at $P < 0.05$. *Results and Conclusions.* Different brand's tubes evaluated can represent a clinically relevant source of variations only on mean platelet volume (MPV) and platelet distribution width (PDW). Basically, our validation will permit the laboratory or hospital managers to select the brand's vacuum tubes validated according to him/her technical or economical reasons for routine hematological tests.

1. Introduction

The procedures involving phlebotomy, for example, time of tourniquet application [1–4] and blood drawing using vacuum tubes [5, 6] are poorly studied as potential sources of errors. In the daily practices of laboratory medicine, several commercial diagnostic products are involved during the testing process. All diagnostic products can be divided into two major categories: in vitro diagnostic (IVD) devices, such as laboratory instruments, reagents, assays, and blood collection tubes, and medical devices, such as specimen collection devices (needles and sets) [7]. Necessary improvements and potential sources of nonconformities, either technical

or concerning the quality management system, shall be identified and all laboratory process shall be validated [8]. Some IVD devices (e.g., blood collection vacuum tubes and syringes for blood analyses) are not validated before the quality laboratory managers decide to start using or to change the brand [9]. Frequently the laboratory or hospital managers select the vacuum tubes for blood collection based on cost considerations or on relevance of a brand [10]. One important question that all quality laboratory managers need to answer is as follows: low cost is synonym of low quality or of large scale production thus implying economy? It is well known that there are several different brands of vacuum tubes for blood collection and a huge competition exists as

for the producers to sell their own IVD devices. The aim of this study was to validate two dry K₃EDTA vacuum tubes of different brands for routine hematological testing.

2. Material and Methods

2.1. Study Design. A group of 100 apparently healthy volunteers from University of Verona, Italy, consented to blood withdrawal after twelve hours fasting. This study was submitted and approved by our Internal Review Board (IRB) and all volunteers signed informed consent.

2.2. Collection of Diagnostic Blood Specimens. The collection of all diagnostic blood specimens was performed by a single, expert phlebotomist, following the international standard from Clinical Laboratory Standard Institute-CLSI [11]. All volunteers were maintained seated during 15 minutes prior to phlebotomy in order to eliminate possible interferences of blood distribution due to different posture [12]. After this interval, a vein was located on forearm by a subcutaneous tissue transilluminator device (Venoscópio IV plus, Duan do Brasil, Brazil) in order to avoid the venous stasis interference [1–3], and two amounts of blood were consecutively drawn by venipuncture with 20 G straight needles (Terumo Europe NV, Leuven, Belgium), directly into two different brands of vacuum tubes containing Ethylenediamine Tetraacetic Acid Tripotassium Salt (K₃EDTA); Tube I: 4.5 mL Labor Import lot 20100505 (concentration of K₃EDTA inside the tube is not made known by Shandong Weigao Group Medical Polymer, Weihai, China); Tube II: 1.2 mL S-Monovette lot 0092201 with 1.6 mg K₃EDTA (Sarstedt, Nümbrecht, Germany). To eliminate any possible interferences due to either the contact phase or the tissue factor, about 2 mL blood were preliminarily collected in a tube without additive Vacuette lot A101004D (Greiner Bio-One GmbH, Kremsmünster, Austria) before the sequence above reported, and then discarded. All the samples were collected into the same type and lot of vacuum tubes.

2.3. Laboratory Testing. All the samples were processed for routine hematological testing immediately after collection (<15 min) on the same Advia 2120i hematology system (Siemens Healthcare Diagnostics, Deerfield, IL, USA). The parameters tested included red blood cells count (RBC), haematocrit (HCT), haemoglobin (HGB), mean red cell volume (MCV), mean red cell haemoglobin content (MCHC), red blood cell distribution width (RDW), white blood cells (WBC) count, and WBC differential, including lymphocytes (LYMPHO), monocytes (MONO), neutrophils (NEU), eosinophils (EOS), basophils (BASO) and large unstained cells (LUC), platelet count (PLT), mean platelet volume (MPV), and platelet distribution width (PDW). The instrument was calibrated against appropriate proprietary reference standard material and verified with the use of proprietary controls. A multicenter evaluation of the within-run precision of the Advia 2120 system showed coefficients of variation ranging from 1.6% to 2.3% for WBC, from 2.1%

to 2.8% for platelets, from 0.6% to 0.9% for RBC, and always lower than 0.7% for hemoglobin, MCV and MCH [13].

2.4. Statistical Analysis. The significance of the differences between two different manufactures of K₃EDTA vacuum tubes for collection of diagnostic blood specimens was assessed by paired Student's *t*-test after checking for normality by the D'Agostino-Pearson omnibus test [14]. As nonnormal distribution was found for MCV, MCHC, RDW, and PDW, results were assessed by Wilcoxon ranked-pairs test. The level of statistical significance was set at $P < 0.05$. Finally, the biases from Tube I and Tube II were compared with the current desirable quality specifications for bias (*B*), derived from biological variation according to the formula $B < 0.25(CV_w^2 + CV_g^2)^{1/2}$ where CV_w and CV_g are, respectively, within- and between-subject CVs, derived from biological variation [15].

3. Results

Results are shown in Table 1. Significant differences were observed for the following: RBC, HCT, MCV, PLT, MPV and PDW. No significant differences ($P > 0.05$) were observed by paired Student's *t*-test for: HGB, WBC, LYMPHO, MONO, NEU, EOS, BASO, and LUC also by Wilcoxon ranked-pairs test in MCHC and RDW. Moreover, clinically significant variations, as compared with the current desirable quality specifications [15], were observed only for MPV and PDW.

4. Discussion

Our results showed that this new vacuum tubes do not represent a clinical relevant new source of error in clinical laboratory for several routine hematological laboratory parameters. Obviously the most prevalent errors and interferences documented [16–25] as regards the preanalytical phase in laboratory medicine need be prevented, and more so it is important to follow the correct procedures for the collection of diagnostic blood specimens by venipuncture that need be respected and observed by all laboratory quality managers [11, 16–26]. Nevertheless, as regards MPV and PDW our results showed that different brands do represent a novel source of variability. During many years the PDW parameter was not considered important by physicians. Moreover, all physicians know that platelet activation is linked with cardiovascular morbidity [27]. Mean Platelet Volume and Platelet Distribution Width are markers of platelet activation [27–31]. Increased MPV is associated with presence and prognosis of vascular disease, including peripheral, cerebrovascular, and coronary artery disease [32], elevated MPV is found even in diabetes mellitus, especially in the presence of microvascular complications [33–36]. Moreover, PDW can be used to evaluate microvascular complication in diabetes patients [37] or to distinguishing thrombocytopenia in pediatric acute lymphocytic leukemia from immune thrombocytopenia [38]. MPV and PDW are higher in nondiabetic patients with severe obstructive sleep

TABLE 1: Variability in hematological parameters from two different brands of K₃EDTA vacuum tubes.

Hematological parameters (unit)	Desirable Bias (%)	Comprehensive results		Mean % difference (<i>P</i> value)
		Tube I	Tube II	
RBC* ($\times 10^6/\mu\text{L}$)	1.7	5.12 \pm 0.41 [4.28–5.71]	5.08 \pm 0.40 [4.31–5.64]	0.8 (< 0.01)
HCT* (%)	1.7	43.5 \pm 3.1 [37.9–49.4]	42.9 \pm 3.1 [36.9–49.1]	1.4 (< 0.01)
HGB* (g/dL)	1.8	14.31 \pm 1.13 [12.80–16.70]	14.29 \pm 1.15 [12.70–16.70]	0.1 (0.56)
MCV** (fL)	1.2	85.9 \pm 6.7 [81.4–87.6]	85.6 \pm 6.7 [81.1–87.0]	0.4 (< 0.01)
MCHC** (pg)	1.4	28.6 \pm 3.1 [26.6–29.3]	28.9 \pm 3.2 [26.6–29.3]	–1.0 (0.87)
RDW** (%)	1.7	12.6 \pm 1.1 [12.4–13.6]	12.6 \pm 1.1 [12.4–13.7]	0.0 (0.94)
WBC* ($\times 10^3/\mu\text{L}$)	5.6	5.80 \pm 1.08 [4.00–7.91]	5.88 \pm 1.11 [3.94–8.01]	–1.4 (0.15)
LYMPHO* ($\times 10^3/\mu\text{L}$)	7.4	1.90 \pm 0.66 [0.81–3.33]	1.92 \pm 0.70 [0.78–3.64]	–1.0 (0.54)
MONO* ($\times 10^3/\mu\text{L}$)	13.2	0.35 \pm 0.13 [0.17–0.69]	0.36 \pm 0.12 [0.21–0.63]	–2.9 (0.27)
NEU* ($\times 10^3/\mu\text{L}$)	9.0	3.35 \pm 0.73 [2.38–4.93]	3.37 \pm 0.72 [2.48–5.09]	–0.6 (0.36)
EOS* ($\times 10^3/\mu\text{L}$)	19.8	0.15 \pm 0.10 [0.02–0.36]	0.15 \pm 0.10 [0.02–0.37]	0.0 (0.75)
BASO* ($\times 10^3/\mu\text{L}$)	15.4	0.041 \pm 0.016 [0.020–0.070]	0.044 \pm 0.020 [0.010–0.090]	–7.3 (0.38)
LUC* ($\times 10^3/\mu\text{L}$)	NA	0.154 \pm 0.048 [0.070–0.260]	0.158 \pm 0.054 [0.070–0.270]	–2.6 (0.41)
PLT* ($\times 10^3/\mu\text{L}$)	5.9	298.3 \pm 61.5 [228.0–431.0]	292.7 \pm 56.3 [224.0–407.0]	1.9 (0.02)
MPV* (fL)	2.3	8.45 \pm 0.69 [7.30–9.80]	8.75 \pm 0.84 [7.40–10.6]	–3.6 (< 0.01)
PDW** (%)	1.4	54.4 \pm 6.6 [48.9–57.2]	51.8 \pm 10.4 [48.8–58.6]	4.8 (<0.01)

* Normal distribution; the values were mean \pm standard deviation (range: minimum–maximum); *P* value represents the significance by paired Student's *t*-test.

** Nonnormal distribution; the values were median \pm standard deviation (5th–95th percentiles); *P* value represents the significance by Wilcoxon ranked-pairs test.

The bold *P* values are statistically significant ($P < 0.05$), and bold mean % differences represent clinically significant variations, when compared with desirable bias [15].

NA: not available [15].

Tube I: 4.5 mL Labor Import lot 20100505 (concentration of K₃EDTA inside the tube is not made known by Shandong Weigao Group Medical Polymer, Weihai, China).

Tube II: 1.2 mL S-Monovette lot 0092201 with 1.6 mg K₃EDTA (Sarstedt, Nümbrecht, Germany).

apnoea syndrome and are correlated with different parameters of breathing function during sleep [39]. An accurate investigation of hematological disorders requires appropriate and discretionary use of laboratory resources. Therefore, total quality in hematological testing is a prerequisite for clinically reliable results [40]. Modern automated hematology counters can provide clinicians with fast results that are characterized by a high degree of precision and accuracy [41]. Nevertheless, it is known that even little details like fasting time, that is not usually solicited for laboratory hematology complete blood count (CBC), can influence the results interpretation [42]. Different tube brands, possibly with small differences in additives may produce appreciable differences in CBC [43]. As regard our findings, the positive aspect is that different brands do not represent a source of variability for RBC count, total and/or differential WBC count, so such relevant parameters of CBC do not undergo an extra analytical issue that could induce mistakes in diagnoses and/or in the followup of patients [21, 23, 24]. We decided to evaluate these brands of K₃EDTA because one is among the most frequently used in Europe and in America laboratory settings where the authors are living, and the other has been newly introduced. Obviously, we would like to encourage more quality's laboratory managers from other countries, for example, from China where many other brands of vacuum tubes are employed, to perform a similar evaluation.

5. Conclusion

Our results showed that different brand's tubes can represent a clinically relevant source of variations on MPV and PDW. The differences observed among dry EDTA vacuum tubes are probably due to the different preparations, for example, (a) dry EDTA particles of different size and delivery inside the vacuum tube, (b) concentration of dry EDTA, (c) materials of tubes and stoppers. Nevertheless, the above issues can add only little to the possible variations if the final user follows the criteria recommended for item 4.6 of ISO15189 [8], thus giving attention to quality first and foremost, giving secondary importance to the price selling issues. We, considering these K₃EDTA vacuum tubes validated for routine laboratory hematology tests.

Conflict of Interests

No potential conflict of interests relevant to this paper was reported.

References

- [1] G. Lima-Oliveira, G. Lippi, G. L. Salvagno et al., "Transillumination: a new tool to eliminate the impact of venous stasis during the procedure for the collection of diagnostic blood

- specimens for routine haematological testing,” *International Journal of Laboratory Hematology*, vol. 33, pp. 457–462, 2011.
- [2] G. Lima-Oliveira, G. L. Salvagno, G. Lippi et al., “Elimination of the venous stasis error for routine coagulation testing by transillumination,” *Clinica Chimica Acta*, vol. 412, no. 15-16, pp. 1482–1484, 2011.
 - [3] G. Lima-Oliveira, G. Lippi, G. L. Salvagno et al., “New ways to deal with known preanalytical issues: use of transilluminator instead of tourniquet for easing vein access and eliminating stasis on clinical biochemistry,” *Biochemia Medica*, vol. 21, no. 2, pp. 152–159, 2011.
 - [4] G. De Souza Lima-Oliveira, G. Picheth, N. M. Sumita, and M. Scartezini, “Quality control in the collection of diagnostic blood specimens: illuminating a dark phase of preanalytical errors,” *Jornal Brasileiro de Patologia e Medicina Laboratorial*, vol. 45, no. 6, pp. 441–447, 2009.
 - [5] J. Rushing, “Drawing blood with vacuum tubes,” *Nursing*, vol. 34, no. 1, p. 26, 2004.
 - [6] G. Lippi, G. L. Salvagno, M. Montagnana, G. Lima-Oliveira, G. C. Guidi, and E. J. Favaloro, “Quality standards for sample collection in coagulation testing,” *Seminars in Thrombosis & Hemostasis*. In press.
 - [7] A. K. Stankovic, J. Silvestri, M. Malis, and C. Najork, “Total quality in laboratory diagnostics: the role of commercial companies,” *Biochemia Medica*, vol. 20, no. 2, pp. 207–214, 2010.
 - [8] ISO, *Medical Laboratories—Particular Requirements for Quality and Competence*, ISO 15189, 2nd edition, 2007.
 - [9] G. Lima-Oliveira, G. Lippi, G. L. Salvagno, M. Montagnana, G. Picheth, and G. C. Guidi, “Different manufacturers of syringes: a new source of variability in blood gas, acid-base balance and related laboratory test?” *Clinical Biochemistry*, vol. 45, no. 9, pp. 683–687, 2012.
 - [10] G. Lima-Oliveira, G. Lippi, G. L. Salvagno, M. Montagnana, G. Picheth, and G. C. Guidi, “Pre analytical management: serum vacuum tubes validation for routine clinical chemistry,” *Biochemia Medica*, vol. 22, pp. 180–186, 2012.
 - [11] Clinical and Laboratory Standards Institute (CLSI), *Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture*, CLSI H3-A6 document, Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 6th edition, 2007.
 - [12] W. G. Guder, S. Narayanan, H. Wisser, and B. Zawta, *Diagnostic Samples: from the Patient to the Laboratory: the Impact of Preanalytical Variables on the Quality of Laboratory Results*, Wiley-Blackwell, 4th edition, 2009.
 - [13] N. Harris, J. M. Jou, G. Devoto et al., “Performance evaluation of the ADVIA 2120 hematology analyzer: an international multicenter clinical trial,” *Laboratory Hematology*, vol. 11, no. 1, pp. 62–70, 2005.
 - [14] R. B. D’Agostino, *Tests for Normal Distribution, Goodness-Of-Fit Techniques*, Macel Decker, 1986.
 - [15] C. Ricós, V. Alvarez, F. Cava et al., “Current databases on biological variation: Pros, cons and progress,” *Scandinavian Journal of Clinical and Laboratory Investigation*, vol. 59, no. 7, pp. 491–500, 1999.
 - [16] P. Bonini, M. Plebani, F. Ceriotti, and F. Rubboli, “Errors in laboratory medicine,” *Clinical Chemistry*, vol. 48, no. 5, pp. 691–698, 2002.
 - [17] P. Carraro and M. Plebani, “Errors in a stat laboratory: types and frequencies 10 years later,” *Clinical Chemistry*, vol. 53, no. 7, pp. 1338–1342, 2007.
 - [18] M. Plebani and P. Carraro, “Mistakes in a stat laboratory: types and frequency,” *Clinical Chemistry*, vol. 43, no. 8, pp. 1348–1351, 1997.
 - [19] G. Lippi, G. L. Salvagno, M. Montagnana, M. Franchini, and G. C. Guidi, “Phlebotomy issues and quality improvement in results of laboratory testing,” *Clinical Laboratory*, vol. 52, no. 5-6, pp. 217–230, 2006.
 - [20] G. Lippi, G. L. Salvagno, G. Brocco, and G. C. Guidi, “Pre-analytical variability in laboratory testing: influence of the blood drawing technique,” *Clinical Chemistry and Laboratory Medicine*, vol. 43, no. 3, pp. 319–325, 2005.
 - [21] G. Lippi and G. C. Guidi, “Risk management in the pre-analytical phase of laboratory testing,” *Clinical Chemistry and Laboratory Medicine*, vol. 45, no. 6, pp. 720–727, 2007.
 - [22] G. Lippi and G. C. Guidi, “Preanalytic indicators of laboratory performances and quality improvement of laboratory testing,” *Clinical Laboratory*, vol. 52, no. 9-10, pp. 457–462, 2006.
 - [23] G. Lippi, R. Fostini, and G. C. Guidi, “Quality improvement in laboratory medicine: extra-analytical issues,” *Clinics in Laboratory Medicine*, vol. 28, no. 2, pp. 285–294, 2008.
 - [24] G. Lippi, A. Bassi, G. Brocco, M. Montagnana, G. L. Salvagno, and G. C. Guidi, “Preanalytic error tracking in a Laboratory Medicine Department: results of a 1-year experience,” *Clinical Chemistry*, vol. 52, no. 7, pp. 1442–1443, 2006.
 - [25] G. Lippi, G. Lima-Oliveira, S. C. Nazer et al., “Suitability of a transport box for blood sample shipment over a long period,” *Clinical Biochemistry*, vol. 44, no. 12, pp. 1028–1029, 2011.
 - [26] Clinical and Laboratory Standards Institute (CLSI), *Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture*, CLSI H3-A5 document, Clinical and Laboratory Standards Institute, Wayne, Pa, USA, 5th edition, 2003.
 - [27] S. Tsiara, M. Elisaf, I. A. Jagroop, and D. P. Mikhailidis, “Platelets as predictors of vascular risk: is there a practical index of platelet activity?” *Clinical and Applied Thrombosis/Hemostasis*, vol. 9, no. 3, pp. 177–190, 2003.
 - [28] I. A. Jagroop, I. Clatworthy, J. Lewin, and D. P. Mikhailidis, “Shape change in human platelets: measurement with a channelyzer and visualisation by electron microscopy,” *Platelets*, vol. 11, no. 1, pp. 28–32, 2000.
 - [29] Y. Park, N. Schoene, and W. Harris, “Mean platelet volume as an indicator of platelet activation: methodological issues,” *Platelets*, vol. 13, no. 5-6, pp. 301–306, 2002.
 - [30] A. Y. Gasparyan, L. Ayvazyan, D. P. Mikhailidis, and G. D. Kitas, “Mean platelet volume: a link between thrombosis and inflammation?” *Current Pharmaceutical Design*, vol. 17, no. 1, pp. 47–58, 2011.
 - [31] E. Vagdatli, E. Gounari, E. Lazaridou, E. Katsibourlia, F. Tsikopoulou, and I. Labrianou, “Platelet distribution width: a simple, practical and specific marker of activation of coagulation,” *Hippokratia*, vol. 14, no. 1, pp. 28–32, 2010.
 - [32] L. Vizioli, S. Muscari, and A. Muscari, “The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases,” *International Journal of Clinical Practice*, vol. 63, no. 10, pp. 1509–1515, 2009.
 - [33] N. Papanas, G. Symeonidis, E. Maltezos et al., “Mean platelet volume in patients with type 2 diabetes mellitus,” *Platelets*, vol. 15, no. 8, pp. 475–478, 2004.
 - [34] Z. Hekimsoy, B. Payzin, T. Örnek, and G. Kandogan, “Mean platelet volume in Type 2 diabetic patients,” *Journal of Diabetes and its Complications*, vol. 18, no. 3, pp. 173–176, 2004.
 - [35] N. Papanas, G. Mavridis, E. Karavageli, G. Symeonidis, and E. Maltezos, “Peripheral neuropathy is associated with increased mean platelet volume in type 2 diabetic patients,” *Platelets*, vol. 16, no. 8, pp. 498–499, 2005.
 - [36] R. Demirtunc, D. Duman, M. Basar, M. Bilgi, M. Teomete, and T. Garip, “The relationship between glycemic control and

- platelet activity in type 2 diabetes mellitus," *Journal of Diabetes and its Complications*, vol. 23, no. 2, pp. 89–94, 2009.
- [37] S. Jindal, S. Gupta, R. Gupta et al., "Platelet indices in diabetes mellitus: indicators of diabetic microvascular complications," *Hematology*, vol. 16, no. 2, pp. 86–89, 2011.
- [38] G. Strauß, C. Vollert, A. von Stackelberg, A. Weimann, G. Gaedicke, and H. Schulze, "Immature platelet count: a simple parameter for distinguishing thrombocytopenia in pediatric acute lymphocytic leukemia from immune thrombocytopenia," *Pediatric Blood and Cancer*, vol. 57, no. 4, pp. 641–647, 2011.
- [39] E. Nena, N. Papanas, P. Steiropoulos et al., "Mean platelet volume and platelet distribution width in non-diabetic subjects with obstructive sleep apnoea syndrome: new indices of severity?" *Platelets*. In press.
- [40] B. A. Jones, F. Meier, and P. J. Howanitz, "Complete blood count specimen acceptability: a College of American Pathologists Q-Probes study of 703 laboratories," *Archives of Pathology and Laboratory Medicine*, vol. 119, no. 3, pp. 203–208, 1995.
- [41] C. Briggs, I. Mellors, A. Roderick et al., "Quality counts: new parameters in blood cell counting," *International Journal of Laboratory Hematology*, vol. 31, no. 3, pp. 277–297, 2009.
- [42] G. Lippi, G. Lima-Oliveira, G. L. Salvagno et al., "Influence of a light meal on routine haematological tests," *Blood Transfusion*, vol. 8, no. 2, pp. 94–99, 2010.
- [43] D. Sears, S. Charache, and M. Perlstein, "Electronic blood cell counters. Faulty calibration due to type and amount of anticoagulant in collection tubes," *Archives of Pathology and Laboratory Medicine*, vol. 109, no. 3, pp. 247–249, 1985.